 Twenty HIV-1 infected individuals will be randomly enrolled into three different study groups, receiving either the gp120NefTatAS02A vaccine 10 individuals, the AS02A adjuvant alone 5 individuals or a placebo 5 individuals. After obtaining informed consent, subjects will have a history and physical exam performed and have laboratory tests to confirm they meet all inclusion and exclusion entry criteria. Women of childbearing potential will have a pregnancy test prior to each injection of the investigational product. Injections with vaccine, adjuvant alone, or placebo will then be performed at weeks 0, 4, and 12. Study participants will undergo close monitoring after each vaccination. Blood samples will be obtained for immunological assays at study baseline 2 times and weeks 2, 4, 6, 12, 14, 24, and 48. All patients will maintain their antiretroviral treatment regimen during the entire study period. 